A clinical team at Baylor Collage of Medicine published promising results on Multi Antigen Targeted T-cell therapy for pancreatic cancer in Nature Medicine.
The study engineered T-cells to recognize multiple tumor antigens, achieving a ~85% disease control rate when combined with standard chemotherapy. Notably, the infused T-cells persisted for up to 12 months, a factor strongly associated with clinical benefit.
Targeting multiple antigens helps overcome tumor heterogeneity and immune escape, two major barriers that have limited earlier T-cell therapies in solid tumors. The treatment also showed a favorable safety profile, supporting its feasibility for further clinical development.
Key takeaway for researchers: Designing therapies that address tumor heterogeneity may be more impactful than intensifying single target immune responses.
Could multi target immune therapies finally unlock treatment options for pancreatic cancer?
MBH/PS